The executive has over 10 years experience in the Laboratory Services industry. The executive has ran regional lab networks and was responsible for M&A at Eurofins Scientific before starting his own lab services company.
This is a snippet of the transcript, sign up to read more.
For example, 10 years ago, most vitamins were actually considered specialty. Today, they are commodity. Routine testing includes full blood counts, vitamins, minerals, and such, which are straightforward, high volume, and unfortunately, have very low margins. Currently, specialty areas include molecular diagnostics and everything related to IVD, women's health, reproductive health, rare diseases, cancer, and tumor diagnostics. But, as I mentioned, by around 2027 or 2028, most of these tests will likely convert into routine.
This is a snippet of the transcript, sign up to read more.
As a clinical diagnostic service provider and a reagent or medtech vendor, the key is to continuously invest in R&D, develop new methods, be faster, more precise, enter new diagnostic areas, and keep developing. This is the only way to stay ahead in this very fast lifecycle of testing within diagnostics or clinical diagnostics.
This is a snippet of the transcript, sign up to read more.
So it really depends on whether you want massive and rapid market share and market expansion, or if you want to mark a difference, taking into account high spending on capex and staff, but actually being able to cross-sell. And I think Cerba Healthcare today is the only player at this stage being able to cross-sell to Eurofins, Biogroup, and Synlab without being a direct competitor to them.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
The executive has over 10 years experience in the Laboratory Services industry. The executive has ran regional lab networks and was responsible for M&A at Eurofins Scientific before starting his own lab services company.